NANOPARTICLES & MICROPARTICLES TO COMBAT ANTIMICROBIAL RESISTANCE
Dr Anjana Jayasree,
Postdoctoral Research Fellow
School of Pharmacy and Pharmaceutical Sciences
The University of Queensland, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Australia | December 2025
Dr Anjana Jayasree is an emerging research leader in biomaterials, tissue engineering and nanotechnology, recognised internationally for her innovative work on antimicrobial nanoparticles and regenerative therapies. A Postdoctoral Research Fellow at The University of Queensland, she operates at the intersection of materials science, drug delivery and cellular biology, developing advanced metallic-based nanotechnologies to improve both human and animal health outcomes. Her expertise spans nanoparticle synthesis, cell–material interactions, and the design of sophisticated in vitro models to investigate soft-tissue integration, osseointegration, angiogenesis and biofilm formation.
A central pillar of Dr Jayasree’s research is the engineering of next-generation metallic implants with precisely tailored surface modifications that enhance cellular attachment while simultaneously minimising bacterial colonisation and biofilm formation. By integrating bioactive ions, nanoscale architectures and smart antibacterial coatings, her work aims to accelerate healing, strengthen soft-tissue integration and significantly reduce implant-associated infection rates. This multidisciplinary program positions her at the forefront of innovation in regenerative dentistry and biomaterials-driven solutions to antimicrobial resistance.
Beyond her research, Dr Jayasree is a passionate advocate for STEM education and public engagement. She contributes to national outreach programs including Soapbox Science, the Kids STEM Convention and the Wonder of Science Young Science Ambassador initiative, inspiring the next generation of scientists through hands-on learning and accessible communication.
Driven, collaborative and highly creative, Dr Jayasree continues to advance impactful research that bridges fundamental science with real-world clinical and industry needs.
Source: Supplied
https://orcid.org/0000-0003-4719-0174
-
Anaemia guidelines updated after 50 years
Professor Sant-Rayn Pasricha is the Acting Deputy Director at the Walter Eliza Hall Institute of Medical Research in Melbourne, Australia. He is also a clinical haematologist at the Royal Melbourne Hospital and the Peter MacCallum Cancer Centre. From a young age, Prof Pasricha dreamed of becoming a doctor and found joy in learning about the human body and how to care for patients. After completing medical school, he developed a passion for working in low and middle-income countries, which led him to spend time working in East Timor, India, and Central Australia with First Nations communities.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Non-invasive tools for CVD screening and monitoring
Dr Hadi Afsharan is a Research Fellow Cardiovascular Science & Diabetes at the Harry Perkins Institute of Medical Research; is a translational research and innovation fellow in medical technologies at The University of Western Australia, holding dual titles as Translational Fellow and Innovation Fellow within UWA’s Medical School and the FHRI (Future Health Research and Innovation) program.
